Early biological markers of post-acute sequelae of SARS-CoV-2 infection. Read more about Early biological markers of post-acute sequelae of SARS-CoV-2 infection.
Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer. Read more about Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer.
Small molecule in situ resin capture provides a compound first approach to natural product discovery. Read more about Small molecule in situ resin capture provides a compound first approach to natural product discovery.
Ambient air pollution and urological cancer risk: A systematic review and meta-analysis of epidemiological evidence. Read more about Ambient air pollution and urological cancer risk: A systematic review and meta-analysis of epidemiological evidence.
Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling. Read more about Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling.
Illuminating the function of the orphan transporter, SLC22A10, in humans and other primates. Read more about Illuminating the function of the orphan transporter, SLC22A10, in humans and other primates.
Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer. Read more about Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer.
VC-resist glioblastoma cell state: vessel co-option as a key driver of chemoradiation resistance. Read more about VC-resist glioblastoma cell state: vessel co-option as a key driver of chemoradiation resistance.
Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment. Read more about Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment.
